Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

FDA puts hold on Inovio Pharmaceuticals trial

Monday, October 31, 2016 6:57
% of readers think this story is Fact. Add your two cents.

Immunotherapy group Inovio Pharmaceuticals Inc (NASDAQ:INO) said the US FDA have put the brakes on a proposed pivotal phase III clinical program  for VGX-3100.

The drug is an immunotherapy targeting cervical dysplasia and reportedly could reach peak yearly sales of up to $500 million if it gains the regulatory green light.

The FDA has placed what’s called a  clinical hold on the trial.

Inovio anticipates receiving a formal letter with complete information from the FDA within 30 days but initially, the organisation says it wants further data to support the shelf-life of the newly designed and manufactured disposable parts of the CELLECTRA 5PSP immunotherapy delivery device.

The study has not yet been started and it has not enrolled or dosed subjects. Moreover, the hold does not relate to any of Inovio’s other ongoing clinical studies.


By midafternoon Monday, Inovio shares were down 16.8% at $6.96.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.